Actively Recruiting
GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2024-12-11
146
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The clinical trial is designed to evaluate the safety and efficacy of GEMOX combined with targeted therapy and immunotherapy for patients with advanced cholangiocarcinoma, and screen the potential biomarkers
CONDITIONS
Official Title
GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, 18 years old 64 70 years old
- ECOG PS scores 0-1
- Expected survival time > 12 weeks
- Advanced cholangiocarcinoma confirmed by histopathology and/or cytology, locally advanced (inoperable) or distant metastasis, with at least one measurable untreated lesion (per RECIST 1.1 criteria)
- No previous systemic or local treatment for the tumor
- Sufficient organ and bone marrow function
You will not qualify if you...
- Other malignant tumors in the past 5 years (except radical basal cell carcinoma or squamous carcinoma of the skin, or radical resected carcinoma in situ)
- Ampullary tumor
- Treatment from other clinical trials within 4 weeks before first dose
- Previous anti-PD-1, anti-PD-L1/L2, anti-CTLA4 antibodies, or other immunotherapy
- Severe cardiovascular disease within 12 months before enrollment (e.g., symptomatic coronary heart disease, congestive heart failure 65 Grade II, uncontrolled arrhythmia, myocardial infarction)
- Uncontrollable pleural effusion, pericardial effusion, or ascites
- Use of steroids or systemic immunosuppressive therapies 4 weeks before enrollment
- Allergic reactions to study drugs
- HIV antibody positive, active hepatitis B or C
- History of allogeneic organ or hematopoietic stem cell transplantation
- Other conditions deemed inappropriate by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Actively Recruiting
Research Team
W
Wei Liu, MD
CONTACT
N
Ningning Zhang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here